Annual Cash & Cash Equivalents
$230.44 M
+$226.28 M+5442.09%
December 1, 2023
Summary
- As of February 20, 2025, BCAX annual cash & cash equivalents is $230.44 million, with the most recent change of +$226.28 million (+5442.09%) on December 1, 2023.
- During the last 3 years, BCAX annual cash & cash equivalents has risen by +$226.28 million (+5442.09%).
- BCAX annual cash & cash equivalents is now at all-time high.
Performance
BCAX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$520.76 M
+$316.90 M+155.46%
September 30, 2024
Summary
- As of February 20, 2025, BCAX quarterly cash and cash equivalents is $520.76 million, with the most recent change of +$316.90 million (+155.46%) on September 30, 2024.
- Over the past year, BCAX quarterly cash and cash equivalents has stayed the same.
- BCAX quarterly cash and cash equivalents is now at all-time high.
Performance
BCAX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BCAX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5442.1% | 0.0% |
| 3 y3 years | +5442.1% | 0.0% |
| 5 y5 years | +5442.1% | 0.0% |
BCAX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5442.1% | at high | +155.5% |
| 5 y | 5-year | at high | +5442.1% | at high | +155.5% |
| alltime | all time | at high | +5442.1% | at high | +155.5% |
Bicara Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $520.76 M(+155.5%) |
| Jun 2024 | - | $203.85 M(-11.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2023 | $230.44 M(+5442.1%) | $230.44 M |
| Dec 2022 | $4.16 M | - |
FAQ
- What is Bicara Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Bicara Therapeutics?
- What is Bicara Therapeutics annual cash & cash equivalents year-on-year change?
- What is Bicara Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Bicara Therapeutics?
- What is Bicara Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Bicara Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of BCAX is $230.44 M
What is the all time high annual cash & cash equivalents for Bicara Therapeutics?
Bicara Therapeutics all-time high annual cash & cash equivalents is $230.44 M
What is Bicara Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, BCAX annual cash & cash equivalents has changed by +$226.28 M (+5442.09%)
What is Bicara Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BCAX is $520.76 M
What is the all time high quarterly cash and cash equivalents for Bicara Therapeutics?
Bicara Therapeutics all-time high quarterly cash and cash equivalents is $520.76 M
What is Bicara Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, BCAX quarterly cash and cash equivalents has changed by $0.00 (0.00%)